Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer

The aim of the research was to study the influence of multiple drug resistance (MDR1), multidrug resistance protein 1 (MRP1) and breast cancer resistance protein (BCRP) proteins expression on the effectiveness of chemotherapy in breast cancer (BC) patients. Patients and Methods: The retrospective an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental Oncology
Datum:2013
Hauptverfasser: Kovalev, A.A., Tsvetaeva, D.A., Grudinskaja, T.V.
Format: Artikel
Sprache:English
Veröffentlicht: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2013
Schlagworte:
Online Zugang:https://nasplib.isofts.kiev.ua/handle/123456789/145262
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Zitieren:Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer / A.A. Kovalev, D.A. Tsvetaeva, T.V. Grudinskaja // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 287-290. — Бібліогр.: 9 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-145262
record_format dspace
spelling Kovalev, A.A.
Tsvetaeva, D.A.
Grudinskaja, T.V.
2019-01-20T08:21:06Z
2019-01-20T08:21:06Z
2013
Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer / A.A. Kovalev, D.A. Tsvetaeva, T.V. Grudinskaja // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 287-290. — Бібліогр.: 9 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/145262
The aim of the research was to study the influence of multiple drug resistance (MDR1), multidrug resistance protein 1 (MRP1) and breast cancer resistance protein (BCRP) proteins expression on the effectiveness of chemotherapy in breast cancer (BC) patients. Patients and Methods: The retrospective analysis of the results of treatment of 77 women with invasive BC with different molecular subtypes at the age of 54.1±12.5, who received treatment in Zaporizhzhya Regional Clinical Oncological Dispensary during 2011–2013, has been carried out. 23 (29.8%) patients were in II stage of disease, 32 (41.5%) — in III stage, 22 patients (28.5%) — IV stage. Neoadjuvant therapy has been given to 34 (44.2%) patients, palliative therapy in connection with presence of hematogenous visceral and bone metastases — to 43 (55.8%) patients. Transport proteins BCRP, MRP and PGP have been studied in tissues of primary BC tumor, in tissues of visceral metastases, in metastatically altered regional lymph nodes, as well as in circulating in blood tumor cells (CTC). In every case, 1000 of tumor cells has been calculated. The intensity of staining (0, 1+, 2+, 3+), percentage of stained cells (threshold has constituted 10%) and homogeneity of tumor cells staining (homogeneous was considered 80% staining of cytoplasm or membrane of studied cells) has been taken in consideration. Results: Retrospective analysis has determined the dependence of results of polychemotherapy (PCT) on level and pattern of expression of BCRP, MRP and PGP proteins. In 1st group, in the absence thereof expression of transport proteins in BC cells, the objective response (CR + PR) from the tumor has been observed in 17 out of 18 patients (94.4%). In 2nd group (only cytoplasmic staining) the objective response has been observed in 36 patients (85.7%). Ineffectiveness of therapy and tumor progression in this group has been observed in 6 (14.2%) patients. In 3rd group (high membrane BCRP, MRP and PGP expression), in 14 out of 17 patients (82.3%), during the PCT occurred progression of the disease. Malignant phenotype of this tumor corresponded with the state of primary multiple drug resistance. In 80.0% of patients of this group, the neoadjuvant therapy turned out to be ineffective. Conclusion: Clinical trials for determination of role of ABC-transporters in the development of drug resistance of BC patients have not yet ended. The leading role in development of resistance of BC cells plays not only PGP, but also MRP1 and BCRP. Marker of resistance is not cytological, but membrane staining of cell.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Special issue on breast cancer
Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer
spellingShingle Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer
Kovalev, A.A.
Tsvetaeva, D.A.
Grudinskaja, T.V.
Special issue on breast cancer
title_short Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer
title_full Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer
title_fullStr Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer
title_full_unstemmed Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer
title_sort role of abc-cassette transporters (mdr1, mrp1, bcrp) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer
author Kovalev, A.A.
Tsvetaeva, D.A.
Grudinskaja, T.V.
author_facet Kovalev, A.A.
Tsvetaeva, D.A.
Grudinskaja, T.V.
topic Special issue on breast cancer
topic_facet Special issue on breast cancer
publishDate 2013
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description The aim of the research was to study the influence of multiple drug resistance (MDR1), multidrug resistance protein 1 (MRP1) and breast cancer resistance protein (BCRP) proteins expression on the effectiveness of chemotherapy in breast cancer (BC) patients. Patients and Methods: The retrospective analysis of the results of treatment of 77 women with invasive BC with different molecular subtypes at the age of 54.1±12.5, who received treatment in Zaporizhzhya Regional Clinical Oncological Dispensary during 2011–2013, has been carried out. 23 (29.8%) patients were in II stage of disease, 32 (41.5%) — in III stage, 22 patients (28.5%) — IV stage. Neoadjuvant therapy has been given to 34 (44.2%) patients, palliative therapy in connection with presence of hematogenous visceral and bone metastases — to 43 (55.8%) patients. Transport proteins BCRP, MRP and PGP have been studied in tissues of primary BC tumor, in tissues of visceral metastases, in metastatically altered regional lymph nodes, as well as in circulating in blood tumor cells (CTC). In every case, 1000 of tumor cells has been calculated. The intensity of staining (0, 1+, 2+, 3+), percentage of stained cells (threshold has constituted 10%) and homogeneity of tumor cells staining (homogeneous was considered 80% staining of cytoplasm or membrane of studied cells) has been taken in consideration. Results: Retrospective analysis has determined the dependence of results of polychemotherapy (PCT) on level and pattern of expression of BCRP, MRP and PGP proteins. In 1st group, in the absence thereof expression of transport proteins in BC cells, the objective response (CR + PR) from the tumor has been observed in 17 out of 18 patients (94.4%). In 2nd group (only cytoplasmic staining) the objective response has been observed in 36 patients (85.7%). Ineffectiveness of therapy and tumor progression in this group has been observed in 6 (14.2%) patients. In 3rd group (high membrane BCRP, MRP and PGP expression), in 14 out of 17 patients (82.3%), during the PCT occurred progression of the disease. Malignant phenotype of this tumor corresponded with the state of primary multiple drug resistance. In 80.0% of patients of this group, the neoadjuvant therapy turned out to be ineffective. Conclusion: Clinical trials for determination of role of ABC-transporters in the development of drug resistance of BC patients have not yet ended. The leading role in development of resistance of BC cells plays not only PGP, but also MRP1 and BCRP. Marker of resistance is not cytological, but membrane staining of cell.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/145262
citation_txt Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer / A.A. Kovalev, D.A. Tsvetaeva, T.V. Grudinskaja // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 287-290. — Бібліогр.: 9 назв. — англ.
work_keys_str_mv AT kovalevaa roleofabccassettetransportersmdr1mrp1bcrpinthedevelopmentofprimaryandacquiredmultipledrugresistanceinpatientswithearlyandmetastaticbreastcancer
AT tsvetaevada roleofabccassettetransportersmdr1mrp1bcrpinthedevelopmentofprimaryandacquiredmultipledrugresistanceinpatientswithearlyandmetastaticbreastcancer
AT grudinskajatv roleofabccassettetransportersmdr1mrp1bcrpinthedevelopmentofprimaryandacquiredmultipledrugresistanceinpatientswithearlyandmetastaticbreastcancer
first_indexed 2025-12-02T07:01:48Z
last_indexed 2025-12-02T07:01:48Z
_version_ 1850861838458159104